ANIK - Anika Therapeutics, Inc.

NasdaqGS - NasdaqGS Delayed Price. Currency in USD
Show:
Income Statement
Balance Sheet
Cash Flow

Income Statement

Annual
All numbers in thousands
Revenue12/31/201612/31/201512/31/2014
Total Revenue103,37992,999105,595
Cost of Revenue24,02721,05320,930
Gross Profit79,35271,94684,665
Operating Expenses
Research Development10,7328,9878,144
Selling General and Administrative18,01314,82515,074
Non Recurring---
Others---
Total Operating Expenses---
Operating Income or Loss50,60748,13461,447
Income from Continuing Operations
Total Other Income/Expenses Net26312058
Earnings Before Interest and Taxes50,87048,25461,505
Interest Expense---
Income Before Tax50,87048,25461,505
Income Tax Expense18,32317,49623,186
Minority Interest---
Net Income From Continuing Ops32,54730,75838,319
Non-recurring Events
Discontinued Operations---
Extraordinary Items---
Effect Of Accounting Changes---
Other Items---
Net Income
Net Income32,54730,75838,319
Preferred Stock And Other Adjustments---
Net Income Applicable To Common Shares32,54730,75838,319